Lisata Therapeutics, Inc.
LSTA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0000320017
No open-market purchases or sales by Lisata Therapeutics, Inc. insiders were filed in the last 90 days; 38 institutions reported holding it in 13F filings for Q3 2026, worth $7.55M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 14, 2026, 1:22 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $16.6M (9756.5% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Feb 27, 2025 | Feb 29, 2024 | Feb 6, 2023 | Mar 22, 2022 |
| Revenue | $170.0K | $1.00M | $0 | – | – |
| Operating expenses | $18.4M | $23.4M | $25.7M | $57.6M | $29.1M |
| Research and development | $7.95M | $11.3M | $12.7M | $13.1M | $17.7M |
| Selling, general and administrative | $10.4M | $12.1M | $13.0M | $14.1M | $11.4M |
| Operating income | -$18.2M | -$22.4M | -$25.7M | -$57.6M | -$29.1M |
| Income tax | -$962.0K | -$798.0K | -$2.33M | -$2.48M | -$1.51M |
| Net income | -$16.6M | -$20.0M | -$20.8M | -$54.2M | -$27.5M |
| EPS, basic | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-0.50 |
| EPS, diluted | $-1.91 | $-2.40 | $-2.58 | $-10.47 | $-0.50 |
| Weighted shares, basic | 8.69M | 8.33M | 8.07M | 5.18M | 55.3M |
| Weighted shares, diluted | 8.69M | 8.33M | 8.07M | 5.18M | 55.3M |
| Margins and growth | |||||
| Operating margin | -10711.2% | -2240.9% | – | – | – |
| Net margin | -9756.5% | -1998.5% | – | – | – |
| Revenue growth, year over year | −83.0% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Feb 27, 2025 | Feb 29, 2024 | Feb 6, 2023 | Mar 22, 2022 |
| Cash and equivalents | $16.0M | $16.2M | $22.6M | $32.2M | $24.6M |
| Accounts receivable | $0 | $900.0K | – | – | – |
| Total current assets | $17.7M | $34.6M | $53.9M | $71.9M | $96.2M |
| Property, plant and equipment | $18.0K | $72.0K | $175.0K | $296.0K | $62.0K |
| Intangible assets | $400.0K | $400.0K | $400.0K | $400.0K | – |
| Total assets | $17.7M | $35.0M | $54.7M | $73.0M | $97.0M |
| Accounts payable | $1.02M | $1.28M | $2.42M | $2.65M | $1.93M |
| Total current liabilities | $3.07M | $5.61M | $6.59M | $6.38M | $4.52M |
| Total liabilities | $3.14M | $5.68M | $6.80M | $6.71M | $5.01M |
| Shareholders' equity | $14.6M | $29.3M | $47.9M | $66.3M | $92.0M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | Feb 27, 2025 | Feb 29, 2024 | Feb 6, 2023 | Mar 22, 2022 |
| Operating cash flow | -$15.9M | -$19.4M | -$20.0M | -$21.2M | -$22.2M |
| Capital expenditures | $28.0K | – | $0 | $285.0K | $60.0K |
| Free cash flow | -$16.0M | – | -$20.0M | -$21.5M | -$22.3M |
| Depreciation and amortization | $146.0K | $174.0K | $189.0K | $69.0K | $55.0K |
| Stock-based compensation | $1.23M | $1.65M | $2.04M | $2.64M | $2.00M |
| Investing cash flow | $15.1M | $13.2M | $10.1M | $28.9M | -$54.9M |
| Financing cash flow | $599.0K | -$206.0K | $385.0K | -$224.0K | $85.3M |
| Net change in cash | -$253.0K | -$6.38M | -$9.56M | $7.51M | $8.13M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 721.2% | 165.3% | – | – | – |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Nov 13, 2026 | 10.8M | +22.5% | SEC |
| Aug 6, 2026 | 9.01M | +2.9% | SEC |
| May 8, 2026 | 9.11M | +5.9% | SEC |
| Apr 23, 2026 | 9.11M | +5.9% | SEC |
| Mar 12, 2026 | 9.03M | +4.8% | SEC |
| Nov 6, 2025 | 8.82M | +5.1% | SEC |
| Aug 7, 2025 | 8.76M | +5.2% | SEC |
| May 8, 2025 | 8.60M | +3.5% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2020, from 13F share counts: 1-for-15 in Q3 2022.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.